Showing 4821-4830 of 8626 results for "".
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meetinghttps://practicaldermatology.com/news/connect-biopharma-to-present-additional-positive-results-from-the-phase-1b-study-of-cbp-201-for-patients-with-moderate-to-severe-ad-at-eadv-virtual-meeting/2460574/Connect Biopharma is slated to present the full results from the Phase 1b study of CPB-201, a novel IL-4R&alpha
- Coping with COVID: Most Psoriasis Patients Taking Immunosuppressants Survive COVID-19https://practicaldermatology.com/news/coping-with-covid-most-pso-patients-taking-immunosuppressants-survive-covid-19/2460573/Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19, according to the first findings from a global registry of psoriasis and COVID-19 patients. The initial findings from the PsoProtect registry, which appear in the
- Industry Responds to COVID-19: TrueHero Face Shieldshttps://practicaldermatology.com/news/truehero-face-shields-offer-reusable-medical-grade-protection/2460572/Responding to the need for PPE across the US, Jamestown Plastics, has pivoted production to manufacture face shields to protect from COVID-19. The TrueHero Extreme Coverage Shield is suitable for medical use, including in dermatology and aesthetic practices.
- SOC, VisualDX, and NEJM Group Launch Webinar Series to Explore Issues in Skin Colorhttps://practicaldermatology.com/news/soc-visualdx-and-nejm-group-launch-webinar-series-to-explore-issues-in-skin-color/2460570/“The Impact of Skin Color and Ethnicity on Clinical Diagnosis and Research,” a new webinar series presented by the Skin of Color Society, NEJM Group, and VisualDx launches this month to call attention to health disparities and structural racism in medicine.
- Alastin SkinCare Hits Canadahttps://practicaldermatology.com/news/alastin-skincare-hits-canada/2460568/Alastin Skincare, Inc. is now available in Caanada via partnership with AVARI Medical Ltd. "Alastin Skincare has established a leadership position in the US, achieving the fastest growth rate in the professional skincare channel for three years in a row. In addition to contin
- Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligohttps://practicaldermatology.com/news/coverage-update-cigna-to-cover-excimer-laser-treatment-for-vitiligo/2460566/Cigna, a global health services company offering health, pharmacy, dental and Medicare plans to both individuals and businesses covering over 20 million people in the United States, has issued a new medical coverage policy for excimer laser therapy vitiligo. STRATA Skin Sciences, maker of the XTR
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology